Bone Biologics (BBLG) Gains from Sales and Divestitures (2016 - 2022)

Bone Biologics (BBLG) reported Gains from Sales and Divestitures of $101166.0 for Q2 2022, up 14.85% quarter-over-quarter from $88083.0 in Q1 2022.

Bone Biologics (BBLG) Gains from Sales and Divestitures (2016 - 2022) Analysis & Trends

Bone Biologics (BBLG) has 3 years of Gains from Sales and Divestitures data on file, last reported at $101166.0 in Q2 2022.

Gains from Sales and Divestitures for Q2 2022 came in at $101166.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2022 was $101166.0 (changed N/A YoY), and the FY2016 annual result was -$791139.0, changed N/A from the prior year.
Gains from Sales and Divestitures climbed to $101166.0 in Q2 2022 per BBLG's latest filing, from $88083.0 in the prior quarter.
Over five years, Gains from Sales and Divestitures peaked at $101166.0 in Q2 2022 and troughed at -$322893.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Bone Biologics	1.45 Mn	1.45 Mn	-

Download Data